FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to immunology and biotechnology. There are presented variants of antagonist antibodies binding to the interleukin-7 receptor (IL-7R). There are described: variants of nucleic acids coding the antibodies; a host cell recombinant producing the antibody; a pharmaceutical composition inhibiting the human IL-7R function, and methods of treating and/or preventing: an autoimmune disease specified in the group of type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis; type 2 diabetes or graft-versus-host disease based on using the antibody.
EFFECT: invention provides the antagonist anti-IL-7R antibodies that can find application in medicine.
17 cl, 15 dwg, 8 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTAGONISTIC ANTIBODIES AGAINST THE IL-7 RECEPTOR AND METHODS | 2014 |
|
RU2653430C2 |
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| ANTIBODIES AND POLYPEPTIDES AGAINST CD127 | 2017 |
|
RU2769352C2 |
| ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND THEIR USE | 2020 |
|
RU2811912C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| ANTIBODIES CAPABLE OF BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2016 |
|
RU2727018C1 |
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| METHODS OF OSTEOARTHRITIS PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING IT | 2006 |
|
RU2429013C2 |
| PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
| TREATMENT OF INTERSTITIAL CYSTITIS | 2008 |
|
RU2570559C2 |
